Focused On-demand Library for Calaxin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9HAE3

UPID:

CLXN_HUMAN

Alternative names:

EF-hand calcium-binding domain-containing protein 1

Alternative UPACC:

Q9HAE3; B4DSB4; E7EVN7

Background:

Calaxin, identified by its alternative name EF-hand calcium-binding domain-containing protein 1, plays a crucial role in cellular motility. It is a key component of the outer dynein arm-docking complex, essential for the binding of outer dynein arms onto microtubules. This protein is pivotal in regulating the assembly of dynein arms and their docking complex, influencing ciliary and flagellar movement. Its function is critical for the determination of body laterality, showcasing its significance in biological systems.

Therapeutic significance:

Understanding the role of Calaxin could open doors to potential therapeutic strategies. Its involvement in ciliary and flagellar motility, essential for numerous physiological processes, highlights its potential as a target for therapeutic intervention in diseases where these processes are disrupted.